Response to Comments: MolDX: Next Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This document (A57909) is a response-to-comments notice relating to MolDX LCD DL38125 for next-generation sequencing lab-developed tests for myeloid malignancies, providing administrative timelines but no clinical coverage criteria. It notes that PGBA MolDx retired A57503 and referenced A57757, which has not been replaced nor adopted by Noridian, so users should refer to LCD DL38125 for actual coverage rules and monitor for adoption of referenced articles.

"PGBA MolDx retired article A57503 and later clarified it as A57757; article A57757 has not been replaced and Noridian has not adopted or implemented A57757."

Sign up to see full coverage criteria, indications, and limitations.